|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reungwetwattana T, Weroha SJ and Molina
JR: Oncogenic pathways, molecularly targeted therapies, and
highlighted clinical trials in non-small-cell lung cancer (NSCLC).
Clin Lung Cancer. 13:252–266. 2012. View Article : Google Scholar
|
|
3
|
Zhang H, Li Z and Wang K: Combining
sorafenib with celecoxib synergistically inhibits tumor growth of
non-small cell lung cancer cells in vitro and in vivo. Oncol Rep.
31:1954–1960. 2014.PubMed/NCBI
|
|
4
|
Hunter AM, LaCasse EC and Korneluk RG: The
inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis.
12:1543–1568. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Danson S, Dean E, Dive C and Ranson M:
IAPs as a target for anticancer therapy. Curr Cancer Drug Targets.
7:785–794. 2007. View Article : Google Scholar
|
|
6
|
Devi GR: XIAP as target for therapeutic
apoptosis in prostate cancer. Drug News Perspect. 17:127–134. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stennicke HR, Ryan CA and Salvesen GS:
Reprieval from execution: the molecular basis of caspase
inhibition. Trends Biochem Sci. 27:94–101. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Holcik M, Gibson H and Korneluk RG: XIAP:
apoptotic brake and promising therapeutic target. Apoptosis.
6:253–261. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ma JJ, Chen BL and Xin XY: XIAP gene
downregulation by small interfering RNA inhibits proliferation,
induces apoptosis, and reverses the cisplatin resistance of ovarian
carcinoma. Eur J Obstet Gynecol Reprod Biol. 146:222–226. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yamaguchi Y, Shiraki K, Fuke H, et al:
Targeting of X-linked inhibitor of apoptosis protein or survivin by
short interfering RNAs sensitize hepatoma cells to TNF-related
apoptosis-inducing ligand- and chemotherapeutic agent-induced cell
death. Oncol Rep. 14:1311–1316. 2005.PubMed/NCBI
|
|
11
|
Jiang C, Yi XP, Shen H and Li YX:
Targeting X-linked inhibitor of apoptosis protein inhibits
pancreatic cancer cell growth through p-Akt depletion. World J
Gastroenterol. 18:2956–2965. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kwatra SG: Targeting X-linked inhibitor of
apoptosis protein for melanoma therapy: the need for more
homogeneous samples and the importance of cell lines. J Invest
Dermatol. 131:7972011. View Article : Google Scholar
|
|
13
|
Hiscutt EL, Hill DS, Martin S, et al:
Targeting X-linked inhibitor of apoptosis protein to increase the
efficacy of endoplasmic reticulum stress-induced apoptosis for
melanoma therapy. J Invest Dermatol. 130:2250–2258. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mastrangelo E, Cossu F, Milani M, et al:
Targeting the X-linked inhibitor of apoptosis protein through
4-substituted azabicyclo[5.3.0]alkane smac mimetics. Structure,
activity, and recognition principles. J Mol Biol. 384:673–689.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Harlin H, Reffey SB, Duckett CS, Lindsten
T and Thompson CB: Characterization of XIAP-deficient mice. Mol
Cell Biol. 21:3604–3608. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang ZL, Fan ZQ, Jiang HD and Qu JM:
Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal
transition in human lung cancer cells via activating MEK-ERK
signaling. Carcinogenesis. 34:638–646. 2013. View Article : Google Scholar
|
|
17
|
Dhawan D, Jeffreys AB, Zheng R, Stewart JC
and Knapp DW: Cyclooxygenase-2 dependent and independent antitumor
effects induced by celecoxib in urinary bladder cancer cells. Mol
Cancer Ther. 7:897–904. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kulp SK, Yang YT, Hung CC, et al:
3-phosphoinositide-dependent-protein kinase-1/Akt signaling
represents a major cyclooxygenase-2-independent target for
celecoxib in prostate cancer cells. Cancer Res. 64:1444–1451. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen ST, Thomas S, Gaffney KJ, Louie SG,
Petasis NA and Schönthal AH: Cytotoxic effects of celecoxib on Raji
lymphoma cells correlate with aggravated endoplasmic reticulum
stress but not with inhibition of cyclooxygenase-2. Leuk Res.
34:250–253. 2010. View Article : Google Scholar
|
|
20
|
Jendrossek V, Handrick R and Belka C:
Celecoxib activates a novel mitochondrial apoptosis signaling
pathway. FASEB J. 17:1547–1549. 2003.PubMed/NCBI
|
|
21
|
Liu X, Yue P, Zhou Z, Khuri FR and Sun SY:
Death receptor regulation and celecoxib-induced apoptosis in human
lung cancer cells. J Natl Cancer Inst. 96:1769–1780. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Menter DG, Schilsky RL and DuBois RN:
Cyclooxygenase-2 and cancer treatment: understanding the risk
should be worth the reward. Clin Cancer Res. 16:1384–1390. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jeon YW and Suh YJ: Synergistic apoptotic
effect of celecoxib and luteolin on breast cancer cells. Oncol Rep.
29:819–825. 2013.
|
|
24
|
Cervello M, Bachvarov D, Lampiasi N, et
al: Novel combination of sorafenib and celecoxib provides
synergistic anti-proliferative and proapoptotic effects in human
liver cancer cells. PLoS One. 8:e655692013. View Article : Google Scholar
|
|
25
|
Morisaki T, Umebayashi M, Kiyota A, et al:
Combining celecoxib with sorafenib synergistically inhibits
hepatocellular carcinoma cells in vitro. Anticancer Res.
33:1387–1395. 2013.PubMed/NCBI
|
|
26
|
Huang KH, Kuo KL, Chen SC, et al:
Down-regulation of glucose regulated protein (GRP) 78 potentiates
cytotoxic effect of celecoxib in human urothelial carcinoma cells.
PLoS One. 7:e336152012. View Article : Google Scholar
|
|
27
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mendez M, Custodio A and Provencio M: New
molecular targeted therapies for advanced non-small-cell lung
cancer. J Thorac Dis. 3:30–56. 2011.
|
|
29
|
Dhawan D, Craig BA, Cheng L, et al:
Effects of short-term celecoxib treatment in patients with invasive
transitional cell carcinoma of the urinary bladder. Mol Cancer
Ther. 9:1371–1377. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu X, Yue P, Schönthal AH, Khuri FR and
Sun SY: Cellular FLICE-inhibitory protein down-regulation
contributes to celecoxib-induced apoptosis in human lung cancer
cells. Cancer Res. 66:11115–11119. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huang S and Sinicrope FA:
Celecoxib-induced apoptosis is enhanced by ABT-737 and by
inhibition of autophagy in human colorectal cancer cells.
Autophagy. 6:256–269. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Davies NM, McLachlan AJ, Day RO and
Williams KM: Clinical pharmacokinetics and pharmacodynamics of
celecoxib: a selective cyclooxygenase-2 inhibitor. Clin
Pharmacokinet. 38:225–242. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gadgeel SM, Ruckdeschel JC, Heath EI,
Heilbrun LK, Venkatramanamoorthy R and Wozniak A: Phase II study of
gefitinib, an epidermal growth factor receptor tyrosine kinase
inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2)
inhibitor, in patients with platinum refractory non-small cell lung
cancer (NSCLC). J Thorac Oncol. 2:299–305. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Agarwala A, Fisher W, Bruetman D, et al:
Gefitinib plus celecoxib in chemotherapy-naive patients with stage
IIIB/IV non-small cell lung cancer: a phase II study from the
Hoosier Oncology Group. J Thorac Oncol. 3:374–379. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Koch A, Bergman B, Holmberg E, et al:
Effect of celecoxib on survival in patients with advanced non-small
cell lung cancer: a double blind randomised clinical phase III
trial (CYCLUS study) by the Swedish Lung Cancer Study Group. Eur J
Cancer. 47:1546–1555. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Holcik M, Yeh C, Korneluk RG and Chow T:
Translational upregulation of X-linked inhibitor of apoptosis
(XIAP) increases resistance to radiation induced cell death.
Oncogene. 19:4174–4177. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wilkinson JC, Cepero E, Boise LH and
Duckett CS: Upstream regulatory role for XIAP in receptor-mediated
apoptosis. Mol Cell Biol. 24:7003–7014. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pan Q, Liu B, Liu J, Cai R, Liu X and Qian
C: Synergistic antitumor activity of XIAP-shRNA and TRAIL expressed
by oncolytic adenoviruses in experimental HCC. Acta Oncol.
47:135–144. 2008. View Article : Google Scholar
|
|
39
|
Ghosh SK, Yigit MV, Uchida M, et al:
Sequence-dependent combination therapy with doxorubicin and a
survivin-specific small interfering RNA nanodrug demonstrates
efficacy in models of adenocarcinoma. Int J Cancer. 134:1758–1766.
2014. View Article : Google Scholar
|
|
40
|
Du Y, Shi A, Han B, et al: COX-2 silencing
enhances tamoxifen antitumor activity in breast cancer in vivo and
in vitro. Int J Oncol. 44:1385–1393. 2014.PubMed/NCBI
|
|
41
|
Xue H, Chen Y, Cai X, et al: The combined
effect of survivin-targeted shRNA and emodin on the proliferation
and invasion of ovarian cancer cells. Anticancer Drugs. 24:937–944.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang Q, Meng X, Zheng G, et al: Antitumor
activity of celecoxib, a selective cyclooxygenase-2 inhibitor, in
medullary thyroid carcinoma. Mol Med Rep. 9:768–772. 2014.
|
|
43
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
44
|
Perez-Tenorio G and Stal O; Southeast
Sweden Breast Cancer Group. Activation of AKT/PKB in breast cancer
predicts a worse outcome among endocrine treated patients. Br J
Cancer. 86:540–545. 2002. View Article : Google Scholar : PubMed/NCBI
|
